Report: Global Pharmaceutical & Biotechnology Outlook 2013: Mature Biotech Report Insights
• Profitable biotech (Mature biotech) and non-profitable biotech companies (Rising stars) have developed innovative drugs for treatment of chronic and non chronic diseases • In the next five years the distinction between mature biotech companies and large global pharma is likely to disappear as investment in R&D and acquisition start delivering and market cap match the large global pharma • Dividend and consolidation could be the future drivers and continue to attract long term investors • Optimism prevails around the future of this sector as a whole which was reflected in the unprecedented rally in shares in 2012 www.researchonglobalmarkets.com